Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.
Explore this paper's citation graph
Summary
The postulated role of excessive activity in the subthalamic nucleus in Parkinson's disease is supported by the effects of lesions evaluated in monkeys rendered parkinsonian by treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- Type
- article
- Published
- 1990-09-21
- Cited by
- 1,962
- References
- 13
- OpenAlex
- https://openalex.org/W2074402500
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32964306
Keywords
Subthalamic nucleus, Parkinsonism, Basal ganglia, Substantia nigra, MPTP
References
- Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey.
- Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys.
- Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii.
- Physiological observations in stereotaxic operations in extrapyramidal motor disturbances.
- Studies on the subthalamus of the rhesus monkey. II. Hyperkinesia and other physiologic effects of subthalamic lesions, with special reference to the subthalamic nucleus of Luys
- Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake.
- What causes membrane fusion in exocytosis?
- The functional anatomy of basal ganglia disorders.
- Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients.
- The mysterious motor function of the basal ganglia
- γ‐Aminobutyric Acid and Benzodiazepine Receptor Changes Induced by Unilateral 6‐Hydroxydopamine Lesions of the Medial Forebrain Bundle
- HEMICHOREA ASSOCIATED WITH A LESION OF THE CORPUS LUYSII
- Experimental hemichorea/hemiballismus in the monkey. Studies on the intracerebral site of action in a drug-induced dyskinesia.
- Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease
Cited by
- Acute monoaminergic depletion in the rat potentiates the excitatory effect of the subthalamic nucleus in the substantia nigra pars reticulata but not in the pallidal complex
- The motor circuit of the human basal ganglia reconsidered.
- Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications?
- The role of excitatory amino acids in experimental models of Parkinson's disease
- Pharmacological pallidotomy with glutamate antagonists?
- Extracellular levels of glutamate and aspartate in the entopeduncular nucleus of the rat determined by microdialysis: regulation by striatal dopamine D2 receptors via the indirect striatal output pathway?
- Sensitization of the striatal dopaminergic system induced by chronic administration of a glutamate antagonist in the rat.
- Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson’s disease
- Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders.
- Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study.
- Medikamentöse Behandlung der idiopathischen Parkinson-Krankheit
- Subthreshold sodium currents and pacemaking of subthalamic neurons: modulation by slow inactivation.
- Deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: evaluation of active electrode contacts
- Brain Oscillations, Medium Spiny Neurons, and Dopamine
- Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease
- Subthalamo‐pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia
- Brain monoamines in progressive supranuclear palsy--comparison with idiopathic Parkinson's disease.
- Deep Brain Stimulation for Psychiatric Disease: Contributions and Validity of Animal Models
- REACHING TO PROPRIOCEPTIVELY DEFINED TARGETS IN PARKINSON’S DISEASE: EFFECTS OF DEEP BRAIN STIMULATION THERAPY
Related papers
- Two cases of unexpected long-term improvement of Parkinson's disease after subthalamic nucleus deep brain stimulation removal
- Deep brain stimulation of the subthalamic nucleus improves sense of well-being in Parkinson’s disease
- Post-Mortem Analysis of Parkinson’s Disease Brains After 11 and 12 Years of Deep Brain Stimulation of the Subthalamic Nucleus
- Various targeting methods for subthalamic nucleus in deep brain stimulation
- PO061 / #228 LONG-TERM OUTCOME OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION FOR PARKINSON’S DISEASE: 10 YEARS AND BEYOND
- Subthalamic nucleus deep brain stimulation for the treatment of secondary dystonia: A case series and review of literature.
- Placement of Deep Brain Stimulators into the Subthalamic Nucleus or Globus pallidus internus: Technical Approach
- Selectively stimulating neural populations in the subthalamic region using a novel deep brain stimulation lead design